๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest

Search Results

Found 7 results for "FDA Warning Letter" across articles, medicines, trials, companies and the glossary

Data Integrity and Quality Oversight: Analyzing the FDA Warning Letter for Sanofi's Waterford Site
Regulatory Affairs
Data Integrity and Quality Oversight: Analyzing the FDA Warning Letter for Sanofi's Waterford Site
Following a January 2026 inspection, the FDA has issued a formal warning letter to Genzyme Ireland Limited in Waterford, citing data integrity concerns, uncontrolled checklists, and quality unit oversight gaps in the manufacturing of Thymoglobulin and Altuviiio.
04 Jul 2026
FDA Fires Warning Shot at Sanofi's Irish Plant Over Data Cover-Up and Altuviiio Quality Failings
Regulatory Affairs
FDA Fires Warning Shot at Sanofi's Irish Plant Over Data Cover-Up and Altuviiio Quality Failings
The FDA has issued a formal warning letter to Sanofi's Waterford facility, Genzyme Ireland Limited, citing data integrity breaches, discarded quality records, and botched deviation investigations in the production of haemophilia drug Altuviiio and transplant therapy Thymoglobulin.
01 Jul 2026
Data Integrity in the Pharmaceutical Quality Control Laboratory: ALCOA+ Principles Explained
Regulatory Affairs
Data Integrity in the Pharmaceutical Quality Control Laboratory: ALCOA+ Principles Explained
An educational review of data integrity requirements in pharma QC, covering ALCOA+ principles, audit trails, and data security.
29 Jun 2026
Out of Specification (OOS) Investigations: Step-by-Step Root Cause Analysis and CAPA Guidelines
Regulatory Affairs
Out of Specification (OOS) Investigations: Step-by-Step Root Cause Analysis and CAPA Guidelines
A structured tutorial on handling quality control laboratory OOS results, conducting Phase I/II investigations, and implementing corrective actions.
29 Jun 2026
Life Science PR in 2026: The Complete Guide to Building Authority, Winning Media Coverage, and Controlling Your Narrative
Biotechnology
Life Science PR in 2026: The Complete Guide to Building Authority, Winning Media Coverage, and Controlling Your Narrative
A definitive 5,000-word guide to public relations for pharmaceutical, biotech, and MedTech professionals. Learn how to build a PR strategy from scratch, which tools to use, how to write for journalists and LinkedIn, and the exact frameworks used by the world's leading life science communications teams.
27 Jun 2026
How to Build a Powerful Personal Brand in Pharma Without Sharing Proprietary Data
Regulatory Affairs
How to Build a Powerful Personal Brand in Pharma Without Sharing Proprietary Data
A complete step-by-step guide for pharmaceutical, biotech and life science professionals on building a credible, visible personal brand on LinkedIn - without ever crossing compliance lines or risking proprietary data exposure. Covers brand strategy, content pillars, storytelling frameworks, and the exact boundaries every pharma professional must respect.
22 Jun 2026
How to Highlight Regulatory Affairs and Compliance Expertise on Your LinkedIn Profile
LinkedIn
How to Highlight Regulatory Affairs and Compliance Expertise on Your LinkedIn Profile
A detailed step-by-step LinkedIn guide for Regulatory Affairs Specialists, Quality Assurance professionals, Pharmacovigilance Officers, CMC Scientists, and all pharmaceutical compliance professionals. Learn exactly how to frame your regulatory expertise on LinkedIn to attract the right roles, visibility, and recognition - without exposing proprietary submissions or confidential regulatory strategy.
22 Jun 2026